Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06821542 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. 3 versions Re-verified since Feb 23, 2026, no change to tracked fieldsv17-v19
  2. Enrollment target: estimated 300 to confirmed 9 Trial status: Recruiting to Active, Not Recruiting · Study sites: 131 to 130v16 Show 2 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 131 to 130
  3. Study sites revised (131)v15 See this version in full on ClinicalTrials.gov ↗
  4. Study sites revised (131)v14 See this version in full on ClinicalTrials.gov ↗
  5. Site details revised at 4 of 131 sitesv13
Show 11 earlier versionsHide 11 earlier versions
  1. Site details revised at 4 of 131 sitesv12
  2. Study sites revised (131)v11 See this version in full on ClinicalTrials.gov ↗
  3. Site details revised at 6 of 131 sitesv10
  4. Study sites revised (131)v9 See this version in full on ClinicalTrials.gov ↗
  5. Site details revised at 1 of 131 sitesv8
  6. Study sites revised (131)v7 See this version in full on ClinicalTrials.gov ↗
  7. Study sites revised (131)v6 See this version in full on ClinicalTrials.gov ↗
  8. Start date changed from estimate of Jun 30, 2025 to Jun 4, 2025v5
  9. Study sites revised (131)v4 See this version in full on ClinicalTrials.gov ↗
  10. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 131v3 Show 1 more changeShow less
    • Study sites: 0 to 131
  11. Study Status, Referencesv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Incyte
94 trials monitored
See 9 trials at risk
This study will be conducted to compare Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy.
Trial Details
NCT Number NCT06821542
Lead Sponsor Incyte Corporation
Conditions Chronic Graft-versus-host-disease
Enrollment 9 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov